NCT06166836 2026-03-25
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Active not recruiting
InxMed (Shanghai) Co., Ltd.
NEC Bio B.V
Fujian Haixi Pharmaceuticals Co., Ltd.
InventisBio Co., Ltd